Changes in Alternative Splicing as Pharmacodynamic Markers for Sudemycin D6

Morgan Thurman, Jacob van Doorn, Barbara Danzer, Thomas R. Webb, Stefan Stamm

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Objective: The aim of the study was to define pharmacodynamic markers for sudemycin D6, an experimental cancer drug that changes alternative splicing in human blood. Methods: Blood samples from 12 donors were incubated with sudemycin D6 for up to 24 hours, and at several time points total RNA from lymphocytes was prepared and the pre-messenger RNA (mRNA) splicing patterns were analyzed with reverse transcription-polymerase chain reaction. Results: Similar to immortalized cells, blood lymphocytes change alternative splicing due to sudemycin D6 treatment. However, lymphocytes in blood respond slower than immortalized cultured cells. Conclusions: Exon skipping in the DUSP11 and SRRM1 pre-mRNAs are pharmacodynamic markers for sudemycin D6 treatment and show effects beginning at 9 hours after treatment.

Original languageEnglish
JournalBiomarker Insights
StatePublished - Sep 11 2017

Bibliographical note

Funding Information:
FunDing: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the NIH. (CA140474 and Clinical and Translational Science Award (CTSA) UL1TR001998); BD was supported by a RISE-DAAD fellowship.

Publisher Copyright:
© 2017, © The Author(s) 2017.


  • Alternative splicing
  • lymphocytes RNA
  • splicing inhibition
  • sudemycin

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Biochemistry, medical


Dive into the research topics of 'Changes in Alternative Splicing as Pharmacodynamic Markers for Sudemycin D6'. Together they form a unique fingerprint.

Cite this